Skip to main content

Persons at Risk for Infection with SARS-CoV-2

Last Updated: April 21, 2020

Pre-Exposure Prophylaxis

The COVID-19 Treatment Guidelines Panel (the Panel) does not recommend the use of any agents for SARS-CoV-2 pre-exposure prophylaxis (PrEP) outside the setting of a clinical trial (AIII).

At present, no agent given before an exposure (i.e., as PrEP) is known to be effective in preventing SARS-CoV-2 infection. Clinical trials using hydroxychloroquine, chloroquine, or HIV protease inhibitors as PrEP are in development or underway.

Post-Exposure Prophylaxis

The Panel does not recommend the use of any agents for SARS-CoV-2 post-exposure prophylaxis (PEP) outside the setting of a clinical trial (AIII).

At present, no agent is known to be effective for preventing SARS-CoV-2 infection after an exposure (i.e., as PEP). Potential options for PEP currently under investigation in clinical trials include hydroxychloroquine, chloroquine, or lopinavir/ritonavir.